Mean arterial pressure, Terlipressin and HRS-AKI
Mean arterial pressure (MAP), terlipressin, and hepatorenal syndrome-acute kidney injury (HRS-AKI) are closely interconnected in the treatment of this severe condition. HRS-AKI is a life-threatening complication of advanced liver disease, characterized by renal dysfunction due to reduced renal perfusion. Terlipressin, a vasopressin analog, is a key pharmacological agent used to reverse HRS-AKI by improving renal blood flow and function.
Relationship Between MAP, Terlipressin, and HRS-AKI:
Terlipressin and MAP: Terlipressin works by causing vasoconstriction in the splanchnic (abdominal) circulation, which redistributes blood flow to vital organs, including the kidneys. This leads to an increase in MAP, a critical factor in improving kidney perfusion and function. In the phase 3 clinical trials (REVERSE and CONFIRM), terlipressin was shown to significantly increase MAP compared to placebo. For instance, on day 1 of treatment, the terlipressin group had a MAP of 85 mm Hg compared to 75 mm Hg in the placebo group, with sustained increases observed over time.
MAP and HRS-AKI Reversal: The post hoc analysis revealed that each 5 mm Hg increase in MAP was associated with a 17% higher likelihood of HRS-AKI reversal (hazard ratio: 1.17). This underscores the importance of MAP as a pharmacodynamic target in the treatment of HRS-AKI.
Mediation Analysis: The study found that MAP mediated the effect of terlipressin on HRS-AKI reversal, with an average of 33% of the treatment effect being mediated through MAP. This indicates that the increase in MAP is a key mechanism by which terlipressin achieves its therapeutic effect.
Conclusion:
Terlipressin effectively increases MAP, which plays a crucial role in reversing HRS-AKI. The findings highlight the importance of monitoring and targeting MAP as part of the therapeutic strategy for managing HRS-AKI.
